EGF-R Positive Non-Small Cell Lung Cancer Clinical Trial
Official title:
Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer: a Single Arm, Phase II Clinical Study
The main purpose of this study is to evaluate the efficacy and safety of Icotinib as neoadjuvant in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer which can be potentially radical treated by surgery.
Patients with EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer which can be potentially radical treated by surgery are arranged to receive Icotinib with a dose of 125 mg three times per day orally for 8 weeks as neoadjuvant therapy; then patients with clinical benefits receive surgical resection of the tumor. If there is curative effect of Icotinib according to the RECIST or pathological report, the patients will continue receive Icotinib for two years as adjuvant therapy after surgery or till progressive disease or unaccepted toxicity. The primary objective of this study is evaluate the efficacy and safety of Icotinib neoadjuvant therapy. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04989322 -
Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC
|
Phase 2 | |
| Recruiting |
NCT03349203 -
Icotinib as Neoadjuvant and Adjuvant Therapy in EGFR-mutant Stage IIIB or Oligometastasis Non-small Cell Lung Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT05998993 -
Study to Evaluate SBRT for EGFR Mutant NSCLC Patients Receiving Osimertinib (CULTRO)
|
N/A | |
| Recruiting |
NCT05033691 -
A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain Metastases
|
N/A | |
| Recruiting |
NCT05256290 -
Phase 1/2 Study of BDTX-1535 in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT04464967 -
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
|
Phase 1/Phase 2 | |
| Completed |
NCT04640870 -
The Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients With Advanced EGFR Mutation-positive Non-small Cell Lung Cancer Treated With Afatinib
|
||
| Active, not recruiting |
NCT04862780 -
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05110950 -
Endobronchial Ultrasound Needle Aspiration With and Without Suction
|
N/A | |
| Completed |
NCT04965701 -
First Line Osimertinib in the Real World: an Inter-regional Prospective Study
|
||
| Recruiting |
NCT06352502 -
An Observational Study of Furmonertinib for EGFR Mutation-positive NSCLC Patients With Brain Metastasis
|
||
| Terminated |
NCT05153408 -
(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC
|
Phase 1 | |
| Not yet recruiting |
NCT05132985 -
Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma
|
Phase 2 | |
| Recruiting |
NCT04504071 -
Dacomitinib in Lung Cancer With Uncommon EGFR Mutations
|
Phase 2 | |
| Recruiting |
NCT05165355 -
Adjuvant Targeted-therapy for Patients With Resected High-risk EGFR-mutant Stage IB-IIA Non-small Cell Lung Carcinoma
|
Phase 2 | |
| Recruiting |
NCT06207292 -
Stereotactic Ablative Radiotherapy in Synchronous and Metachronous Oligo-Metastatic Non Small Cell Lung Cancer
|
N/A | |
| Recruiting |
NCT05573373 -
Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer
|
Phase 1 | |
| Recruiting |
NCT05263947 -
Bevacizumab Combined With Double Dose Icotinib in Patients With EGFR Exon 21-L858R Mutation
|
Phase 2 | |
| Not yet recruiting |
NCT06287593 -
The Feasibility of Dynamic Liquid Biopsy Monitoring During Neoadjuvant Treatment for EGFR-mutated NSCLC
|
N/A |